Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...

Intellia Therapeutics reported further progress with two treatments that are now ensconced in Phase III of testing. Click ...

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) just released its latest quarterly results and things are looking bullish. Revenues of US$17m beat estimates by a substantial 39% margin. Unfortunately, ...

Analysts expect Intellia Therapeutics to report an earnings per share (EPS) of $-1.27. Anticipation surrounds Intellia ...

In the first quarter, the FDA granted Intellia the RMAT designation for nex-z for the treatment of ATTR with cardiomyopathy, which follows prior RMAT designations received for nex-z for ATTR with ...

Intellia Therapeutics NTLA incurred a loss of $1.10 per share (including one-time expenses of change in fair value of investments) in the first quarter of 2025, which was narrower than the Zacks ...

CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...

Intellia Therapeutics, Inc. announced key operational and financial updates for the first quarter of 2025, highlighting significant progress in its clinical trials. The company is on track to ...

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexi ...